Core Insights - Ginkgo Bioworks has achieved its $250 million annualized cost-reduction goal three months ahead of schedule, driven by financial discipline and restructuring efforts [2][9][24] - The company reported a total revenue of $50 million for Q2 2025, a decrease from $56 million in the same period last year, with notable growth in Cell Engineering revenue [9][15] - Ginkgo's strategic positioning includes expanding its service offerings in response to increasing demand in the biopharma industry and securing major government contracts [2][9] Financial Performance - Total revenue for Q2 2025 was $50 million, down from $56 million in Q2 2024 [9] - Cell Engineering revenue increased to $39 million, up 8% from $36 million in the prior year [9] - Biosecurity revenue decreased to $10 million, down from $20 million in the comparable prior year period [9] - GAAP net loss for Q2 2025 was $(60) million, significantly improved from $(217) million in Q2 2024 [9] - Adjusted EBITDA improved to $(28) million from $(99) million in the prior year [9] Business Highlights - Ginkgo's Automation and Datapoints offerings are becoming essential tools in AI-powered bioengineering [9] - The company launched a new in vitro ADME profiling service, enhancing its capabilities in preclinical R&D analytical services [9] - Ginkgo introduced its first direct-to-scientist product, a cell-free protein synthesis system optimized for high production [9] Outlook - Ginkgo reaffirms its total revenue guidance for 2025 to be between $167 million and $187 million [9] - The company expects Cell Engineering revenue to be between $117 million and $137 million in 2025 [9] - Biosecurity revenue is projected to be at least $40 million in 2025 [9]

Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON, July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available ...

Core Insights - Ginkgo Bioworks has been selected by the Environmental Molecular Sciences Laboratory (EMSL) to deliver an automated anaerobic phenotyping platform, marking a significant advancement in biological research and bioeconomy leadership [1][6] - The contract, valued at $4.66 million, involves constructing a fully integrated workcell with 18 devices within a modular anaerobic chamber, designed to enhance laboratory efficiency and data quality [3][4] - Ginkgo Automation's Reconfigurable Automation Cart (RAC) technology will enable remote operation of complex workflows, streamlining research processes and accelerating discovery in microbial engineering and biodesign [4][5] Company Overview - Ginkgo Bioworks focuses on making biology easier to engineer, providing customizable R&D solutions across therapeutics, diagnostics, and manufacturing [7] - The company offers modular laboratory automation systems that allow scientists to focus on planning and analyzing experiments rather than manual tasks [7] - Ginkgo's automation technology has been deployed in various labs, resulting in increased throughput, repeatability, and reduced cycle times [5][6]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 6.31% in its stock price, closing at $13.96, while the S&P 500 gained 0.4% [1] - Over the past month, the company's shares have increased by 55.05%, significantly outperforming the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61% [1] Earnings Projections - The upcoming earnings disclosure for Ginkgo Bioworks is projected to show an earnings per share (EPS) of -$1.44, which reflects a 55% increase from the same quarter last year [2] - Revenue is estimated to be $43 million, indicating a 23.5% decrease compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict an EPS of -$5.56 and revenue of $180 million, representing changes of +46.33% and -20.72% from the previous year, respectively [3] - Recent changes to analyst estimates for Ginkgo Bioworks are important as they indicate the evolving nature of near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Position - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record of outperformance, with 1 stocks returning an average of +25% annually since 1988 [5] - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 95, placing it in the top 39% of over 250 industries [6] - The strength of individual industry groups is measured by the Zacks Industry Rank, which is based on the average Zacks Rank of individual stocks, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - Ginkgo Bioworks has launched a cost-effective, high-throughput ADME profiling service aimed at accelerating small molecule drug discovery, with a focus on providing model-ready datasets and competitive pricing compared to international vendors [1][2][3] Company Overview - Ginkgo Bioworks is positioned as a leading platform for cell programming and biosecurity, offering integrated laboratory automation and large lab datasets to support AI model development [4] New Service Features - The new ADME profiling service is designed to enhance the drug development pipeline for small molecules, providing early access to rich ADME data that empowers researchers to prioritize candidates and train predictive models efficiently [2][6] - Key features include automated workflows, cost-effective pricing with a price match guarantee against international vendors, and rapid turnaround times to align with modern discovery cycles [6][3] Leadership Statement - Jason Kelly, co-founder and CEO of Ginkgo Bioworks, expressed confidence that the new ADME service will be transformative for drug discovery, emphasizing the company's ability to offer competitive pricing and quality through automation and scale [3]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.60, reflecting a +1.8% change from the previous day's closing price, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, the company's shares have appreciated by 10.29%, contrasting with the Medical sector's decline of 3.4% and the S&P 500's increase of 4.51% [1] Upcoming Financial Results - Ginkgo Bioworks is expected to report earnings of -$1.44 per share, indicating a year-over-year growth of 55%, while revenue is projected to be $43 million, representing a 23.5% decline compared to the same quarter last year [2] - For the annual period, the Zacks Consensus Estimates predict earnings of -$5.56 per share and revenue of $180 million, reflecting changes of +46.33% and -20.72% respectively from the previous year [3] Analyst Estimates and Stock Performance - Changes in analyst estimates for Ginkgo Bioworks are crucial as they indicate shifting business trends, with positive revisions suggesting analyst optimism about profitability [3] - The Zacks Rank system, which evaluates these estimate changes, currently assigns Ginkgo Bioworks a rank of 2 (Buy), indicating a favorable outlook [5] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [6]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.79, reflecting a -2.53% change from the previous day's closing price, underperforming the S&P 500's daily gain of 0.28% [1] - The stock has increased by 13.19% over the past month, outperforming the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Earnings Projections - The upcoming EPS for Ginkgo Bioworks is projected at -$1.44, indicating a 55.00% increase compared to the same quarter last year [2] - Quarterly revenue is estimated at $43 million, which is a decrease of 23.5% from the year-ago period [2] - For the entire year, the Zacks Consensus Estimates forecast earnings of -$5.56 per share and revenue of $180 million, reflecting changes of +46.33% and -20.72% respectively compared to the previous year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Ginkgo Bioworks are important as they reflect short-term business trends and can indicate analyst optimism about the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, provides an actionable rating system for investors [5] - Ginkgo Bioworks currently holds a Zacks Rank of 2 (Buy), with the consensus EPS estimate remaining unchanged over the last 30 days [6] Industry Context - Ginkgo Bioworks is part of the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [7] - The top 50% rated industries tend to outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - Meta Platforms, Inc. is restructuring its AI strategy by forming a new division called Meta Superintelligence Labs, aimed at creating superintelligence that surpasses human cognitive abilities [1][5] - Alexandr Wang, the former CEO of Scale AI, has been appointed as Chief AI Officer to lead this new division, emphasizing a unified leadership approach [1][2] Strategic Investments and Talent Acquisition - Meta has made a significant investment of $14.3 billion for a 49% stake in Scale AI, securing Wang's leadership and enhancing its AI capabilities [3] - The company is actively recruiting top AI talent from industry leaders such as OpenAI, DeepMind, and Anthropic, with Zuckerberg personally involved in the recruitment process [3] Leveraging Open-Source and In-House Innovations - Meta's AI initiatives will utilize open-source Llama 3 models and proprietary MTIA chips to reduce dependence on expensive NVIDIA hardware, aiming for optimized performance and cost-efficiency [4] Vision for the Future - Zuckerberg expressed confidence in Meta's ability to deliver personal superintelligence, highlighting the company's strong business foundation and experience in reaching billions of users [5]

Company Overview - Ginkgo Bioworks Holdings, Inc. (DNA) shares increased by 18.9% to close at $11.25, with a notable trading volume compared to typical sessions, and a total gain of 36.1% over the past four weeks [1][2] Investor Sentiment - The surge in stock price is linked to positive investor expectations regarding Ginkgo's proprietary cell programming platforms, Foundry and Codebase, which are utilized in R&D services under collaboration and license agreements [2] Financial Performance Expectations - The company is projected to report a quarterly loss of $1.44 per share, reflecting a year-over-year increase of 55%, while revenues are expected to be $43 million, down 23.5% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 12.1% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - Ginkgo Bioworks is part of the Zacks Medical - Biomedical and Genetics industry, where Novavax (NVAX) has seen a decline of 1.1% to $6.3, with a return of -13.2% over the past month [5] - Novavax's consensus EPS estimate has decreased by 46.9% over the past month to -$0.12, representing a year-over-year change of -112.1% [6]

Core Insights - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls, surpassing Regeneron Pharmaceuticals' previous offer of $256 million in a bankruptcy auction [1][2] - The deal is expected to close soon, pending a court hearing scheduled for June 17 [1] - 23andMe filed for bankruptcy in March due to declining demand and a data breach in 2023 that compromised sensitive customer information [2][6] Company Developments - 23andMe's bankruptcy filing was a result of a significant decline in consumer demand for DNA testing services [2][6] - The company faced legal challenges, with New York and over two dozen other states suing to contest the sale of its customers' private information [3] - TTAM Research Institute, associated with Wojcicki, has committed to upholding 23andMe's existing privacy policies and complying with data protection laws [2] Competitive Landscape - Regeneron Pharmaceuticals initially offered $256 million for 23andMe, which was later outbid by Wojcicki's nonprofit [1][5] - Regeneron expressed willingness to make a new bid but requested a $10 million breakup fee if Wojcicki's bid is accepted [5]